Back to Agenda
Session 3: Asia's Role in Drug Development: A Global and Regional Perspective
Session Chair(s)
Romi Singh, PhD
Head, Regional Regulatory Sciences, Asia
Pfizer Inc, United States
Tomas Salmonson, DrMed, PhD
Partner
Critical Path Institute, United States
Historically, drug registrations in Asia followed, and to a large extent depended on, the Western drug development. However, over the recent years, there has been an increasing trend of Asia becoming a hub of global drug innovation and development. This session will discuss how Asia contributes to the global drug development and provide examples of how data generated primarily in Asia is used for registration in the West (US, EU).
Speaker(s)
Contribution of Asia in Execution of Global Clinical Trials
Yoshimasa Shimoto, PhD
Daiichi Sankyo Co., Ltd., Japan
Vice President, Asia Development (Region Head)
Asia's Role in Drug Development - an European Perspective
Tomas Salmonson, DrMed, PhD
Critical Path Institute, United States
Partner
Concept of Adaptive Licensing and Its Feasibility for a New Pathway of Drug Development from the Regional and Global Regulators' Perspective
Raymond S.B. Chua, MD, MBA, MPH, FRCP
Ministry of Health, Singapore
Deputy Director of Medical Services, Health Regulation Group
Have an account?